arGEN-X SE

06/23/2024 | Press release | Distributed by Public on 06/24/2024 02:03

argenx SE, - argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE

argenx SE

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date23 jun 2024 - 18:04
Statutory nameargenx SE
Titleargenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy